Effect of etoposide plus thalidomide as maintenance therapy on progression-free survival of elderly patients with advanced non-small cell lung cancer

被引:1
|
作者
Yanan Ge [1 ]
Zhendong Zheng [1 ]
Zhaozhe Liu [1 ]
Jianing Qiu [1 ]
Xiaodong Xie [1 ]
机构
[1] Department of Oncology,General Hospital of Shenyang Military Region
关键词
etoposide; thalidomide; advanced non-small cell lung cancer(NSCLC); maintenance therapy;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
Objective The aim of the study was to evaluate the efficacy and safety of etoposide plus thalidomide as maintenance therapy for elderly patients with advanced non-small cell lung cancer(NSCLC) without disease progression after first-line chemotherapy.Methods After four to six cycles of platinum-based first-line therapy, 64 elderly patients with advanced NSCLC without disease progression who were treated in the General Hospital of Shenyang Military Region(China) from 2014 to 2016 were enrolled in this study. According to the different maintenance treatment methods, patients were divided as having received etoposide plus thalidomide therapy(treatment group, n = 32) and best supportive care(control group, n = 32). Disease control and progression-free survival(PFS) were compared between the two groups. Results The recent curative effect objective response rates of the treatment group and the control group were 31.3% and 3.1%, respectively, and the disease control rates were 71.9% and 31.3%, respectively. The Kaplan-Meier survival curves of the two groups were significantly different(χ2 = 26.532, P = 0.001). The median PFS for the treatment group and control group was 6.0 months [95% confidence interval(CI) = 4.3–7.9 months] and 3.2 months(95% CI = 2.6–3.8 months), respectively. The side effects in the treatment group included hematologic abnormalities, gastrointestinal toxicity, and impaired liver function, which were relieved after symptomatic support therapy and drug withdrawal.Conclusion Etoposide plus thalidomide as maintenance therapy is associated with a significantly longer PFS with tolerable toxicity for elderly patients with advanced NSCLC.
引用
收藏
页码:103 / 107
页数:5
相关论文
共 50 条
  • [1] Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy
    Bhatt, P.
    Bonomi, P.
    Basu, S.
    Batus, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S868 - S869
  • [3] Effect of antimicrobial therapy on progression-free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer
    Uhlenbruch, Mark
    Krueger, Stefan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5915 - 5919
  • [4] Effect of antimicrobial therapy on progression-free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer
    Mark Uhlenbruch
    Stefan Krüger
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5915 - 5919
  • [5] Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy
    Uhlenbruch, Mark
    Kruger, Stefan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2079 - 2082
  • [6] Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy
    Mark Uhlenbruch
    Stefan Krüger
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2079 - 2082
  • [7] Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone
    Zhigang Wei
    Xin Ye
    Xia Yang
    Guanghui Huang
    Wenhong Li
    Jiao Wang
    Xiaoying Han
    Medical Oncology, 2015, 32
  • [8] Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone
    Wei, Zhigang
    Ye, Xin
    Yang, Xia
    Huang, Guanghui
    Li, Wenhong
    Wang, Jiao
    Han, Xiaoying
    MEDICAL ONCOLOGY, 2015, 32 (02)
  • [9] Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients
    Arrieta, O. G.
    Barron, F.
    Carmona, A.
    Ramirez-Tirado, L.
    Zatarain Barron, Z. L.
    Cardona, A. F.
    Bautista, Y.
    Aldaco, F.
    Lazaro, M.
    Baez, R.
    Gerson, R.
    Blanco, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S291 - S291
  • [10] Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer
    Wang, Ying
    Yang, Jin
    Lu, You-Jin
    LUNG, 2015, 193 (06) : 1057 - 1057